Pay Infected Blood Compensation
Conservative · what the evidence says
An independent, source-checked look at Conservative’s policy “Pay Infected Blood Compensation” — what it would actually do across the things that affect your life. Every claim below quotes the source behind it. How this works.
Public finances & the next generation — Hurts
moderate · low confidence
Paying infected blood compensation will cost around £12.8 billion according to the National Audit Office, which has already been allocated in budgets — but early modelling suggested total costs could exceed £20 billion, so the final bill to public finances is uncertain. The scheme adds significantly to public expenditure, though whether it is deficit-financed or offset elsewhere cannot be determined from the evidence provided.
The evidence
- The policy commits to paying comprehensive compensation to infected and affected individuals, including a further £210,000 interim payment to living infected beneficiaries. — conservatives.com (manifesto) — “providing a further £210,000 interim payment to living infected beneficiaries”
- The Autumn Budget 2024 allocated £11.8 billion for infected blood compensation. — commonslibrary.parliament.uk (government) — “The Autumn Budget 2024 allocated £11.8 billion for infected blood compensation”
- The NAO estimated the scheme would cost £12.8 billion overall as of April 2026. — commonslibrary.parliament.uk (government) — “This was later estimated by the National Audit Office to be £12.8 billion overall as of April 2026”
- An additional £1 billion was allocated in April 2026 for changes to the scheme. — theguardian.com (media) — “An additional £1 billion was allocated in April 2026 for changes to the scheme”
- Earlier financial modelling suggested total compensation costs could exceed £20 billion, significantly higher than the £12.8 billion allocated. — commonslibrary.parliament.uk (government) — “Early financial modelling examined by ministers suggested total compensation could exceed £20 billion, significantly higher than the £11.8 billion (later £12.8 billion) allocated in the Autumn Budget 2024”
- The NAO estimates between 8,500 and 16,500 infected people and around 51,000 affected people could be eligible. — commonslibrary.parliament.uk (government) — “The NAO estimated that between 8,500 and 16,500 infected people could claim compensation, and around 51,000 affected people might also be eligible, though they noted considerable uncertainty in these figures”
- The £210,000 further interim payment to living infected beneficiaries has already been committed. — commonslibrary.parliament.uk (government) — “A further interim payment of £210,000 has been committed to living infected beneficiaries”
Biggest unknown: Whether the £12.8 billion allocation proves sufficient or whether the final cost approaches the £20 billion+ figure from earlier financial modelling, and whether the spending is deficit-financed or balanced by offsetting measures.
Our reading: This policy commits to a large, specific fiscal expenditure: comprehensive infected blood compensation totalling approximately £12.8 billion per the NAO, with £11.8 billion allocated in the Autumn Budget 2024 and a further £1 billion added in April 2026. The £210,000 interim payment reaffirmed in the policy text is already committed per the evidence, so the marginal fiscal impact of this specific policy statement is limited — the bulk of the cost is already priced into budgets. Nonetheless, the aggregate spending is substantial. The key O12 question is sustainability: is this funded or deficit-financed? The evidence does not specify whether the allocations are offset by revenue measures or are borrowed, so this verdict rests on the scale of spending alone. On that basis, a fiscal commitment of £12.8 billion — potentially rising to over £20 billion per earlier modelling — represents a clear worsening of the near-term debt path relative to a counterfactual of not paying. The uncertainty in beneficiary numbers (8,500–16,500 infected; ~51,000 affected, with 'considerable uncertainty') means the final liability could materially exceed current allocations. Confidence is low because: (a) the total cost range is wide; (b) the evidence does not reveal whether spending is deficit- or tax-financed; and (c) the policy statement largely reaffirms existing commitments rather than adding new net fiscal impulse. The direction is nonetheless worsens — large unfunded-or-partially-funded public expenditure, with upside cost risk — at moderate magnitude given the sums involved, felt primarily within this parliament as payments roll out.
Cost of living — Helps
moderate · moderate confidence
This policy pays substantial financial compensation to people harmed by contaminated blood products, directly improving their ability to afford essentials after years of hardship. The main caveat is that payments are rolling out slowly, and many eligible people are still waiting — some dying before receiving anything.
The evidence
- The policy commits to a further £210,000 interim payment to living infected beneficiaries, accepting inquiry principles for comprehensive compensation. — conservatives.com (manifesto) — “providing a further £210,000 interim payment to living infected beneficiaries”
- A further interim payment of £210,000 has been committed to living infected beneficiaries. — commonslibrary.parliament.uk (government) — “A further interim payment of £210,000 has been committed to living infected beneficiaries”
- As of May 2026, only around 3,232 people had received payments out of 18,530 registered claims. — hepctrust.org.uk (media) — “3,232 people had received payments out of 18,530 claims registered”
- Compensation payments do not adversely affect eligibility for means-tested benefits, protecting recipients' other income support. — impact.ed.ac.uk (academic) — “they do not adversely impact eligibility for means-tested benefits”
- For recipients, compensation offers financial stability and well-being after years of hardship. — ibca.org.uk (media) — “compensation offers a degree of financial stability and a sense of well-being after years of hardship and neglect”
- Charities report that victims are dying without receiving compensation, meaning the cost-of-living benefit is not reaching all intended recipients. — hepctrust.org.uk (media) — “Charities report that victims are dying without receiving the compensation they are due, adding to their distress”
Biggest unknown: Whether the scheme will accelerate payments quickly enough to reach the tens of thousands still waiting, given that as of May 2026 only around 3,200 of over 18,500 registered claimants had received payments.
Our reading: The policy directly improves the cost of living for a specific, identifiable group — people infected and affected by contaminated blood products — by transferring substantial sums of money to households that have experienced long-term financial and physical harm. The stated £210,000 interim payment per living infected person is material; at this scale it meaningfully improves real disposable income and ability to afford essentials. The protection of means-tested benefit eligibility ensures the payment does not displace other support, amplifying the net financial gain for lower-income recipients. However, the improvement is 'moderate' rather than 'major' at the population level because the scheme is restricted to a defined cohort of victims rather than the general public, and because delivery is significantly lagging: with only ~3,200 of 18,500+ claimants paid as of May 2026, the practical cost-of-living benefit has not yet reached most eligible people. The slow rollout and reports of victims dying before payment mean the real-world effect is currently partial. The policy's commitment to accepting inquiry principles and providing the additional interim payment is the marginal contribution here — it reaffirms and extends a scheme already underway, offering some acceleration for living infected beneficiaries specifically.
Equal treatment & democratic rights — Helps
moderate · moderate confidence
This policy commits to paying compensation to victims of the infected blood scandal, providing formal recognition and financial redress after decades of denial — a meaningful step toward equal treatment and justice for a wronged group. The main caveat is that delivery is slow, with thousands still waiting and some dying before receiving payments.
The evidence
- The policy commits to paying comprehensive compensation to infected and affected individuals, accepting inquiry principles, and providing a further £210,000 interim payment to living infected beneficiaries. — conservatives.com (manifesto) — “pay comprehensive compensation to those infected and affected by the infected blood scandal, accepting inquiry principles and providing a further £210,000 interim payment to living infected beneficiaries”
- The Infected Blood Inquiry described the scandal as the worst treatment disaster in the history of the NHS and made 12 recommendations forming the basis of the compensation scheme. — commonslibrary.parliament.uk (government) — “The Inquiry's final report in May 2024 described the scandal as "the worst treatment disaster in the history of the NHS" and made 12 recommendations, all accepted by the government in full or in principle, forming the ba…”
- Over 30,000 people were infected between the 1970s and early 1990s, with thousands more affected. — impact.ed.ac.uk (academic) — “Over 30,000 people were infected between the 1970s and early 1990s, with thousands more affected”
- The scheme provides recognition and acknowledgment of the severe long-term mental, physical, social, and economic impacts suffered by victims and their families. — cambridge.org (media) — “The scheme represents a crucial acknowledgment of the severe long-term mental, physical, social, and economic impacts suffered by victims and their families”
- Recognition is described as a significant step towards justice after decades of being denied redress. — cambridge.org (media) — “This recognition is a significant step towards justice, particularly after decades of being denied redress and adequate support”
- A further interim payment of £210,000 has been committed to living infected beneficiaries. — commonslibrary.parliament.uk (government) — “A further interim payment of £210,000 has been committed to living infected beneficiaries”
- As of May 2026, only 3,232 people had received payments out of 18,530 claims registered. — hepctrust.org.uk (media) — “By May 7, 2026, 3,232 people had received payments out of 18,530 claims registered”
- Charities report that victims are dying without receiving the compensation they are due. — hepctrust.org.uk (media) — “Charities report that victims are dying without receiving the compensation they are due, adding to their distress”
- The government widened eligibility to include pre-1982 HIV infections and increased compensation for chronic Hepatitis C sufferers, addressing some earlier concerns about exclusion. — thorntons-law.co.uk (media) — “The government has since addressed some of these concerns by widening eligibility to include pre-1982 HIV infections and increasing compensation for chronic Hepatitis C sufferers, as well as expanding eligibility for adu…”
Biggest unknown: Whether the scheme will be delivered quickly and fully enough to reach all eligible victims in their lifetimes, given that as of mid-2026 only around 3,200 of potentially 60,000+ eligible people had received payments.
Our reading: The infected blood scandal represents one of the clearest cases of the state failing a group of citizens and then denying them redress for decades. Compensation schemes of this kind bear directly on O9: they provide formal legal recognition that a group was wronged, restore a measure of equal treatment under the rule of law, and deliver due process to people who were denied it. The policy commits to comprehensive compensation on inquiry principles — a strong stated commitment grounded in an independent judicial inquiry's findings. The £210,000 further interim payment is a concrete, quantified instrument, not merely aspirational language. The scheme is already partially operational: over £2 billion paid to more than 3,000 people, with eligibility broadened since launch to address earlier exclusions of pre-1982 HIV infections and Hepatitis C sufferers. This is real delivery, not just intent. The magnitude is moderate rather than major because delivery is severely lagging: as of May 2026 only 3,232 of 18,530 registered claimants had received payments, and charities report victims dying before receiving compensation. The policy's stated commitment adds an incremental improvement (the additional £210,000 interim payment) to an already-established scheme, but the fundamental bottleneck is pace of delivery, not the existence of the commitment. Confidence is moderate: the scheme exists and is paying out, but the gap between commitment and delivery is wide and well-documented.